Two Sigma Investments, LP Palatin Technologies Inc Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.34 - $0.86 $8,145 - $20,603	-23,957 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$0.44 - $0.63 $1,151 - $1,648	-2,616 Reduced 9.84%	23,957 $11,000
Q2 2021 Aug 16, 2021	SELL	$0.48 - $0.72 $71,077 - $106,616	-148,079 Reduced 84.79%	26,573 $16,000
Q1 2021 May 17, 2021	SELL	$0.68 - $1.25 $113,177 - $208,046	-166,437 Reduced 48.8%	174,652 $120,000
Q4 2020 Feb 16, 2021	BUY	$0.38 - $0.78 $59,978 - $123,113	157,838 Added 86.13%	341,089 $231,000
Q3 2020 Nov 16, 2020	SELL	$0.47 - $0.64 $47,965 - $65,314	-102,054 Reduced 35.77%	183,251 $87,000
Q2 2020 Aug 14, 2020	SELL	$0.41 - $0.73 $15,895 - $28,301	-38,769 Reduced 11.96%	285,305 $146,000
Q1 2020 May 15, 2020	SELL	$0.36 - $0.79 $7,341 - $16,109	-20,392 Reduced 5.92%	324,074 $137,000
Q4 2019 Feb 14, 2020	BUY	$0.75 - $0.89 $51,077 - $60,611	68,103 Added 24.64%	344,466 $269,000
Q3 2019 Nov 14, 2019	SELL	$0.78 - $1.09 $8,665 - $12,109	-11,110 Reduced 3.86%	276,363 $251,000
Q2 2019 Aug 14, 2019	BUY	$0.98 - $1.64 $281,723 - $471,455	287,473 New	287,473 $333,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $8.27M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.